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 LIST OF ABBREVATIONS 
 
Hb   : Haemoglobin  
mm  : Millimeter 
Vs  : Versus 
min  : Minutes 
PR  : Pulse Rate 
BP  : Blood Pressure 
DBP  : Diastolic Blood Pressure 
SBP  : Systolic Blood Pressure 
DM  : Diabetes Mellitus 
L.L.L.T : Low level laser therapy 
US – FDA : United States Food and Drugs Administration  
Laser   : Light Amplification by Stimulated of Emission of Radiation 
 ABSTRACT 
 
Efficacy of low level laser therapy in diabetic wound healing 
diabetic wound healing dynamics  
 
A Randomized Control Trial 
 
Research question : Is low level laser therapy given once in three 
days for 20 days ( 7 sessions)  cluster probe at 2.5 m w at a dose of                      
8 - 10 J/cm2, CO2 Laser along with conventional therapy compared to 
conventional therapy alone effective in reducing the mean percentage in area 
reduction in diabetic foot ulcer participants treated in coimbatore medical 
college. 
 
Objective:  
 
To determine mean percentage reduction of wound area in either group  
 
Study design: 
 
A randomized control study from oct 2007 – sep 2009 
 
Setting: 
 
Coimbatore Medical College Hospital, Coimbatore  
 
Sample size: 
 
Forty participants (20 in each group) with type II diabetes with foot 
ulcers who fulfilled the eligibility criteria participated in the study. 
 
 
 Randomization procedure:  
 
Randomization was done  using a computer generated randomization  
chart. 
Method : 
 
After the initial wound measurement on day 1,  study group received 
L.L.L.T with conventional  therapy (saline or betadine dressings) for a period 
of 20 days  while the control group received only conventional therapy (Saline 
or Betadine dressings). Wound was reassessed for area reduction on day 20.  
 
Out come measures: 
 
Percentage of area of wound  reduction   were measured using unpaired 
student T Test 
 
Results: 
 
  Participants in the study group had better mean percentage wound 
contraction 41.17% as compared to the control group 15.55% (p<0.001 
Z=7.08).  
 
Conclusion : 
 
Low level laser therapy can be used as an adjunct to conventional 
therapy for the healing of diabetic foot ulcers. 
 
Key words: diabetic foot, low level laser therapy  
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INTRODUCTION 
 
  The incidence of diabetes and its complications are on a rise, the risk 
of lower extremity amputations is 15 fold  higher  in diabetics as compared 
to non – diabetics. essential to mention here that chronic diabetic foot ulcer 
is the leading cause of amputations in these patients, also that 15% of all 
diabetics develop  diabetic ulcer and the most commonest site being the foot. 
although the fundamental pathophysiologic factors leading to diabetic ulcer  
remain incompletely  understood. The triad  of neuropathy. Ischemia and 
infections commonly is considered  the most important. These diabetic 
ulcers are known to be resistant to conventional treatment and may herald 
severe complications if not treated wisely. 
 
Research findings to date based upon animal, human and most 
notably invitro cellular studies have certainly established the fact, that low 
level laser therapy can play a major, adverse effect free useful role in 
healing chronic diabetic ulcers resistant to the conventional mode of 
treatment.  
 
Reports of low laser therapy applied to soft tissues in vitro and in 
vivo suggest stimulations of specific healing processes in healing wounds. A 
common  feature of these studies are that while low does of laser therapy are 
simulative the higher doses are suppressive. 
 
Major changes seen in the wounds treated with low level laser 
therapy include increased granulation tissue, increased granulation tissue, 
increased fibroblast proliferation, collagen synthesis, epithelializaion and 
enhanced neovascularizatin. In humans, anecdotal clinical observations of 
small case studies have suggested that low level laser therapy stimulates the 
process of healing. A criticism of many in vivo experimental designs to 
examine the efficacy of low level laser therapy has been lack of control, port 
experimental design, inequality among the control and the study groups  
  2
and inadequate specification of treatment settings, because of very few 
studies in humans and previous studies with ill defined controls and poorly 
defined and documented  parameters we felt the need to undertake this 
study.60 various studies have been performed to improve the understanding 
of low level laser therapy effects at cellular level. Early research suggested 
laser mediated improvements in wound healing recent cold laser studies 
have further focused on laser  impact on cell growth. Because fibroblasts 
play a crucial role in wound  healing, most of the studies published in the in 
the LLT literature5 have examined the effects LLT on fibroblast  cell 
growth, locomotion and production of collagen,  in early 90;s a direct and 
massive  transformation of cultured fibroblasts into my fibroblasts was 
observed as early as 24 hours after laser treatment; this in vitro induction 
may be analogous to that of in vivo. Thus induction of a phenotype with 
contractile properties may have clinical significance in the acceleration of 
wound healing.  
 
More recently studies done on effects of LLLT irradiation on cell15 
proliferation of he la cells also showed encouraging results and most of the 
effects observed were at molecular level. Growth curves of all cell 
population were increased regardless of cell irradiation, though most 
encouraging results were encountered after 24 to 96 hrs after irradiation. 
Most studies were done in a pulsed frequency of 5 kHz and energy densities 
between 4 – 12 J/ cm24 
 
Most of the research  work done with respect to LLLT has been with 
recalcitrant ulcers, venous ulcers3, pressure sores radiation ulcers. There are 
a few case reports and some poor quality studies on diabetic foot ulcers15. 
Indirect evidence in a study suggest improvement in skin circulation in 
patients with diabetic microangiopathy due to athermic effects of laser 
irradiation. Another study used topical hyperbaric oxygen and LLLT in 
treatment of chronic diabetic foot ulcers with positive outcome and stated 
that LLLT may be safe and simple treatment in such patient.  
  3
Hence to keep the controls and the study group alike as much as 
possible a triple blind sham controlled study was done to assess the efficacy 
of LLLT on incised wounds in experimental human model and were 
observed for wound contraction, colour change, and luminance, the study 
supported the fact that LLLT improves healing rates in superficial incised 
wounds, but again these subjects were not diabetics, and the efficacy in 
diabetic patients  still remains obscure.  
 
In view of inadequate studies regarding the efficacy of LLLT in 
diabetic wound healing dynamics we undertook this study to know whether 
low level laser therapy given daily with clustered probe at 2.5mW at 5KHz 
frequency, 10,600 nm wavelength, 2 – 5 min at a dose of 8 - 10 J/cm2 along 
with conventional treatment compared to conventional therapy alone, is 
effective in reducing the mean percentage in area reduction, In patients 
with diabetic foot ulcers more than 3 weeks old admitted in cmch under 
surgery department.  
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AIMS AND OBJECTIVE 
 
¾ To test the efficacy of low level carbon - dioxide [CO2] laser therapy 
with conventional therapy vs conventional therapy alone in Type 2 
diabetic foot ulcer patients treated in Coimbatore Medical College 
Hospital Coimbatore, between October 2007 and September 2009. 
 
¾ To determine mean percentage of wound area reduction in either 
group. 
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REVIEW OF LITERATURE 
 
HEALING 
 
Definition  
 
“Body replacement  of destroyed tissues by the living tissue” or 
“integrated series of cellular & biochemical events which restores the 
functional integrity & regains the strength of injured tissue” 
 
Phases of Healing 
 
Wound healing & repair are complex processes that involves 
dynamic series of event [Reddy G.K.2001] 
 
¾ Coagulation 
¾ Inflammation 
¾ Fibroplasias, angiogenesis, proliferation & granulation tissue 
formation  
¾ Epitheliazation  
¾ Collagen synthesis 
¾ Wound contraction / tissue remodeling / scar maturation  
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HISTORICAL BACKGROUND OF LASER 
 
The word LASER is an acronym for Light Amplification by 
Stimulated Emission of Radiation 
According to the European standard IEC 601, the definition of laser 
is “any device which can be made to produce or amplify electromagnetic 
radiation in the wavelength range from 180 nm to 1 mm, primarily by the 
process of controlled stimulated emission”. 
 
TABLE No 3.1: HISTORICAL BACKGROUND OF THERAPEUTIC LASER 
Scientist Year  Contribution Made in Development of Laser
Albert 
Einstein 
1916 Principle on which lasers are based were postulated. 
Credit for the development of laser theory  is generally 
given to Elbert Einstein. In his theory “Zur Quantum 
Theories Der Strahlung”, published in 1916, he first used 
the name “stimulated emission”. 
Mester Et al 1985 Non invasive lasers were introduced into medicine in 
1980’s, since then, have gained wide application in many 
areas of health care. 
Lam TA Et al 
 
1986 Although the beneficial effects of laser photostimulation
are now generally accepted, the mechanism by which 
laser facilitates the wound healing & tissue repair, is yet 
to be clearly understood 
Lysons Rf 1987 
Kert Et al 1989 The non invasive low power lasers up to 500 mw have 
been reported to have stimulatory, anti – inflammatory & 
analgesic effects 
Meller mm 1990 The beam of laser energy is coherent, polarized, focused 
& monochromatic. 
Schindl A et al 1998 – 
2000 
Low energy lasers are effective as analgesic & accelerates 
the healing of injured tissues.  
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COLD LASER 
 
 
Lasers used in field of medicine are known as cold lasers. The power 
levels of light are greatly amplified by the emission of radiation from 
stimulation of specific substances.  Every substance radiates emission in 
varying wavelengths and frequencies.  Helium, neon, cobalt, and carbon 
dioxide are examples of substances that, when irradiated, have application 
in commercial, medical or engineering processes. 
 
MECHANICS 
 
 
 
To obtain the laser, a tube filled with a gaseous mixture of helium 
and neon is stimulated electrically to emission levels.  Within the highly 
reflective, polished walls of the tube, the molecules reverberate and carom 
off the walls in a highly agitated state, building energy as they do so.  When 
a critical level is reached, the flow of energy literally “bursts” through the 
semi silvered (similar to one-way mirror) front end of the tube   and is 
channeled along an optic fiber to the beam applicator or probe for clinical 
applications. 
 
 
LASER PHYSICS 
 
Intensity 
 
 
One might naturally assume that the laser generates tremendous 
power; however, the type of laser used by physical therapist has the 
intensity of only one m W-less than the power of a 60-W commonly used 
light bulb!  The commercial and industrial (i.e. hot lasers) range in the 
thousands and millions of watts and are used for cutting, drilling and 
destructive applications.  The tool used by physical therapists, a cold laser, 
is used primarily for healing and other nondestructive purposes. 
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PHYSICAL CHARACTERISTICS 
 
There are three characteristics of laser light that clearly differentiate 
it from ordinary light. 
 
I-MONOCHROMATICITY 
 
Ordinary light is comprised of a conglomeration of many wave 
lengths, commonly known as ROYGBIV, or the visible spectrum of Red, 
Orange, Yellow, Green, Blue, Indigo, and Violet, all merging to produce 
“white” light.  Laser light, however, consists of one wave length only which 
is 6,328 A units.  Because this wave length falls within the R section of the 
visible spectrum (3,900 to 7,700 A units), the laser light of 6,328 A units is a 
brilliant red color. 
 
2-COHERENCE 
 
Because the wave lengths of ordinary light are so variable and do not 
“match” in wave forms, frequencies, or shapes, there is much scrambling 
of wave forms, cancellation and reinforcements of individual waves, and 
interference in the production of energy in general; this factor minimizes 
the power of ordinary light as an energy source.  The identical wave lengths 
and forms, that comprise laser light, lead to great amplification since the 
“waves and troughs” of the radiation are reinforced.  Because they are 
parallel and in line with each other, they are termed coherent. 
 
3-NON-DIVERGENCE 
 
The laser beams unique in the absolute “straightness” of the 
directed radiation.  Ordinary light shines in all directions (e.g. consider a 
light bulb radiating in all directions).  The sun is another example of omni 
directional radiation.  The laser, on the other hand, shines in only one 
direction, not unlike a flashlight, although its beam is far more 
concentrated and narrowed.  The divergence of a laser beamed to the 
surface of the Moon and Earth showed a deflection of just a few meters 
after a journey of more than 260,000 miles. 
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4. OUTPUT POWER = STRENGTH (W/Mw) 
 
¾ Power is measured in watts (W). the strength or power output of a 
laser is thus measured in watts or milliwatts (mW=A thousand of 
watt) 
 
¾ Higher output power means higher power density, which is often 
desirable  
 
 
¾ In addition, a higher output power means that a certain desired dose 
(input energy. Measured in joules per cm2 of skin) is more quickly 
reached because energy is the same as power multiplied by time.  
 
 
ENERGY : 
 
   Joules   =  Power (mW) X Time (Sec) 
 
   Eg  Joules  =  2.5mW X4sec 
 
   =  10J/cm2 
 
PHYSIOLOGY 
1. WOUND HEALING 
 
Ordinary light does not penetrate the skin or underlying tissues.  
Only the retina can absorb the visible spectrum.  As discussed previously, 
infrared is absorbed at the 3-mm level and ultraviolet at the 1-mm level.  
Research has indicated that the 6,328 A unit wave length of the cold laser 
may stimulate intracellular structures and functions.  One of the prime 
applications of laser light in physical therapy is that of wound healing. 
 
2. ANALGESIC EFFECTS 
 
In pain control, the penetration of laser light is often compared with 
an acupuncture needle.  Therefore, when the laser is used for analgesic 
purposes, the beam is generally directed at acupuncture points, trigger 
points, and nerve roots, as is done with acupuncture. 
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3. PENETRATION 
 
Direct penetration of the 6,328 A unit HeNe cold laser at I m W said 
to be approximately 0.8mm; indirect penetration after reflection, 
dispersion, reflection, and partial absorption is 10 to 12mm. 
 
4. ABSORPTION 
 
Absorption is apparently dependent on the resonance of the tissues 
or on the subject’s water content.  Many of the penetration characteristics 
and limitation factors are determined by fluids (e.g. water, blood). 
 
PHYSICAL EFFFECTS 
1. HEATING 
 
  A mild but reversible heat is produced   with the cold laser.   The 
tissues revert back to the pre-lasting temperatures immediately following 
radiation.  Although the thermodynamics involved do not produce a 
therapeutic level, cell wall permeability has been shown to be a favorable 
result of heat and may play a role in the reaction of the laser on the cell 
wall. 
 
2. DEHYDRATION 
 
Loss of water following radiation is another reversible process.  Such 
loss may be attributed to the minor heating and/or the transfer of fluids to 
distant sites.  Apparently, it does not play a major role in the laser’s 
effectiveness. 
 
3. COAGULATION OF PROTEINS, THERMOLYSIS, AND 
EVAPORATION 
 
 Coagulation of proteins, Thermolysis, and evaporation are 
irreversible and should not occur with the dosages and techniques used by 
physical therapists.  Coagulation is a permanent process, comparable to 
that of an egg frying in a skillet.  Thermolysis or “melting from heat” is 
also a lasting state.  Evaporation, of course, involves the transformation of  
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liquids to the gaseous state and is not easily reversed.  With competent 
clinicians and sophisticated equipment, none of these conditions should be 
produced in routine administration of the cold laser.  With higher power 
levels, one must be cautious and aware of the above factors.  
 
 
INDICATIONS 
 
Cold laser is indicated for treating: 
¾ Open lesions 
¾ Decubitus ulcers 
¾ Diabetic ulcers 
¾ Lacerations 
¾ Incisions 
¾ Burns 
¾ Chronic and acute pain especially those of musculoskeletal origin.  
For example, arthritis, sprains tendonitis, contusions, lumbago, 
neuralgia, neuritis. 
¾ Restricted joint ranges of motion 
 
CONTRINDICATIONS 
 
¾ Do not radiate the eye directly. 
 
¾ Whether is suspected due to its mobilizing effect on steroids in the 
human system. 
 
¾ Do not use the laser with patients who are naturally photosensitive or 
who are photosensitized by medication. 
 
¾ Patients with pacemakers (Since the electronic circuits of the laser 
system could interfere with the operation of the pacemaker). 
 
¾ Patients with left ventricular insufficiency under treatment for poor 
peripheral circulation (since laser treatment might produce a 
dangerous overloading of the central venous system). 
 
¾ Patients with recent heart attacks. 
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RISK OF EYE INJURY  
 
 Even in the infancy of laser technology there was an awareness of 
the increased risk of eye damage compared to conventional light sources, 
hence, new rules introduced to handle this hazard, lasers were divided into 
five categories (class 1,2,3A,3B and 4) according to their potential to 
damage the eye.  
 
TABLE NO 3.2 : RISK OF EYE INJURY 
 
Class Safety with Regard to Eye Damage
Classes 1-3A Are considered safe
Class 3B Involves a certain risk
Class 4 Definite risk
Comprises strong industrial and surgical lasers capable 
of burning and cutting  
 
 Note that this classification has nothing to do with the medical use, 
efficiency or quality of lasers but refers solely to the possible risk of eye 
injury.  
 
THE FOLLOWING AREAS SHOULD NEVER BE IRRADIATED: 
 
¾ Eyes and pregnant uterus as mentioned above. 
 
¾ Thyroid glands (due to the possibility of increased hormone 
secretion). 
 
¾ Male external genitalia (due to the possibility of interaction with the 
cells of the germinal line or the endocrine portion of the testicle  
 
¾ Skin if there is cutaneous or subcutaneous bacterial infection. 
 
¾ Growing cartilage in children. 
 
  13
 
 
PRECAUTIONS 
 
 
Poor results may ensure in patients: 
 
 
¾ Of extreme age 
¾ Under heavy medication 
¾ With thick eschar 
¾ With considerably scar tissue 
¾ With extremely dry skin 
¾ With active infection 
 
A touch of moisture on the tip of probe or the target skin may 
enhance the electrical contact needed for efficient point searching.  
Perspiration or other skin moisture will naturally give false read-outs; 
adjustments must be made in such circumstances.  Dry the patient’s skin 
to lasing and/or select higher readings on the LED for targeting. 
 
 
WOUND HEALING & REPAIR 
 
 
PRINCIPLE OF ARNDT – SCHULTZ 
 
¾ If the quantity of energy is too small to stimulate the absorbing 
tissues, NO significant reaction will take place.  
 
¾ If the quantity of energy absorbed per unit of time is adequate to 
stimulate, the absorbing tissue will perform its normal function.  
 
¾ It the quantity for energy is too great, per unit time, the absorbing 
tissue will be disrupted and cannot perform its normal function.  
 
¾ Local tissue temperatures SHOULD NOT be elevated above 45oc 
that tissue destruction is likely to occur.  
¾ Therefore proper selection of laser dose is necessary to prevent photo 
– inhibitory effects (as it works on the principle of ARNDT – 
SCHULTZ). 
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¾ Effects of LLLT are photochemical not thermal and the responses of 
cells occurs due to changes in photo acceptor molecules (also known 
as chromophores molecules which are able to absorb photonic 
energy) such as porphyrin.  
 
¾ The exact mechanism of action of LLLT is not completely  
understood. However, it is known  that during laser irradiation cells 
absorb photonic energy  that is incorporated into chromophores, 
which in turn, stimulates cellular metabolism  
 
¾ The chromophores is able to transfer the absorbed energy to other 
molecules and thus cause chemical reactions in surrounding tissue.  
 
DOSAGE 
 
 Actual dosages with the cold laser depend on the power factor, 
duration of radiation, and tissue resonance.  
 
WOUND HEALING 
 
 
 In most wound healing applications, the prescribed dosage is 10,600 
nm wavelength, 2-10 sec/cm2 of open lesion. This may require several 
minutes of hand – held direction of the beam over the surface of the wound 
so that each square centimeter is exposed for the same 2-10 seconds. The 
probe tip is held approximately 2 to 3 mm from the surface to obtain a 
“Disc” of laser light about 1 cm in diameter on the surface of the wound. 
The non – divergent nature of the laser is modified by a lens – like 
spreading of the beam for therapeutic  purposes.  
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LASERS IN MEDICINE AND SURGERY 
 
 In the table below, the names, wavelengths, working modes, and 
uses of the most common laser systems used in medicine are listed.  
 
TABLE NO 3.3  : CLASSIFICATION OF THERAPEUTIC LASERS 
LASER NAME WAVELENGTH 
(NM) 
PULSED OR 
CONTINUOUS  
 
MEDICAL USE 
Crystalline laser Medium 
KTP / 532 532 nm p/c Leg Vein Treatment 
Ruby 694 P Tattoo & Hair 
Removal
Alexandrite 755 P Bone Cut, Hair 
Removal
ND : YAG 1064 P Coagulation of 
Tumors 
HO : YAG 2130 P Surgery, Root Canal, 
lithotripsy 
ER : YAG 2940 P Dental Drill, Laser 
Peeling 
Ti: Sapphiere Tunable  P Two Photon PDT 
Semiconductor Lasers 
InGaAIP 630-700 C Biostimulation 
Liquid laser medium  
Dye Laser  Tunable  P/C Kidney Stones 
Gas Lasers 
Excimer 193, 248, 308 P Eye, Vascular Surgery 
Argon 350-514 C Dermatology, 
Retinopathy
Copper 578 P/C Dermatology 
HeNe 633,3390 C Biostimulation 
Co2 10600 P/C Dematology, Surgery 
 
  16
 
THE PRODUCTION OF LASER RADIATION BY 
CARBON DIOXIDE LASER 
 
 
 The carbon dioxide laser (CO2 laser) was one of the earliest gas 
lasers to be developed (invented by Kumar Patel of Bell Labs in 1964[1]), 
and is still one of the most useful. Carbon dioxide lasers are the highest-
power continuous wave lasers that are currently available. They are also 
quite efficient: the ratio of output power to pump power can be as large as 
20%. 
 The CO2 laser produces a beam of infrared light with the principal 
wavelength bands centering around 9.4 and 10.6 micrometers. 
AMPLIFICATION 
 The active laser medium (laser gain/amplification medium) is a gas 
discharge which is air cooled (water cooled in higher power applications). 
The filling gas within the discharge tube consists primarily of: 
• Carbon dioxide (CO2) (around 10–20 %)  
• Nitrogen (N2) (around 10–20%)  
• Hydrogen (H2) and/or xenon (Xe) (a few percent; usually only used 
in a sealed tube.)  
• Helium (He) (The remainder of the gas mixture)  
 The specific proportions vary according to the particular laser. 
The population inversion in the laser is achieved by the following 
sequence: 
1. Electron impact excites vibrational motion of the nitrogen. Because 
nitrogen is a homonuclear molecule, it cannot lose this energy by 
photon emission, and its excited vibrational levels are therefore 
metastable and live for a long time.  
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2. Collisional energy transfer between the nitrogen and the carbon 
dioxide molecule causes vibrational excitation of the carbon dioxide, 
with sufficient efficiency to lead to the desired population inversion 
necessary for laser operation.  
 
3. The nitrogen molecules are left in a lower excited state. Their 
transition to ground state takes place by collision with cold helium 
atoms. The resulting hot helium atoms must be cooled in order to 
sustain the ability to produce a population inversion in the carbon 
dioxide molecules. In sealed lasers, this takes place as the helium 
atoms strike the walls of the container. In flow-through lasers, a 
continuous stream of CO2 and nitrogen is excited by the plasma 
discharge and the hot gas mixture is exhausted from the resonator 
by pumps.  
 
 The CO2 laser can be constructed to have CW powers between 
milliwatts (mW) and hundreds of kilowatts (kW).[2] It is also very easy to 
actively Q-switch a CO2 laser by means of a rotating mirror or an electro-
optic switch, giving rise to Q-switched peak powers up to gigawatts (GW) 
of peak power[3]. 
 
 
 
  18
 
 
 
DIABETES MELLITUS 
Definition  
 
“Diabetes mellitus is characterized by chronic hyperglycemia with 
disturbances of carbohydrate, fat, and protein metabolism resulting from 
defects in insulin secretion, insulin action, or both”.  
 
Depending on the etiology of the DM, factors contributing to 
hyperglycemia may include: 
 
¾ Reduced insulin secretion 
¾ Decreased glucose utilization 
¾ Increased glucose production  
 
Or 
 
“Level of glycaemia at which diabetes specific complications occur 
rather than on deviations from population based mean” 
 
Epidemiology of the diabetic foot syndrome 
 
¾ A quarter of the diabetic population is at increased risk of foot 
injuries as a result of the presence of diabetic neuropathy or an 
arterial circulatory disorder. Every year 3 to 7% of diabetics suffer a 
foot lesion for the first time. 
 
¾ Foot ulcers occur in approximately 15% of people with diabetes 
which accounts for 25% of all hospital admissions with the hospital 
stay being 60% longer than the stay for other causes and the risk of 
amputation is 15 to 40 times greater in diabetics that in others. 
 
¾ Diabetic foot ulcers account for more than 50% of non traumatic 
amputations and are associated with high rates of mortality. Re – 
amputation and contra lateral limb amputation.  
 
¾ India has 30 million diabetics at present and in the year 2025 India is 
predicted to have  57 million diabetics.  
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INCIDENCE IN INDIA 
 
Foot ulcer     :  1-4% 
Toe amputation     : 2.6% 
Below knee amputation    : 1.6% 
Prevalence of diabetic foot in India  : 5.3 – 10.5% 
 
SOCIO – ECONOMIC IMPACT OF THE DIABETIC FOOT SYNDROME 
 
¾ Overall, the costs generated by diabetes are about three times as 
high as those produced by non – diabetics. Foot complications 
constitute a major proportion of these. 
 
¾ With primary  healing, about 30% of the total cost derives from 
hospitalization, but where amputation is required this  figure is 65% 
to 80% the average healing duration for diabetic foot lesions is about 
four months. 
 
¾ Ten percent of all lesions persist for more than one year, which 
incurs further costs for outpatient care. Fifteen percent of all foot 
ulcers in diabetics do not heal before the patient’s death 
 
¾ Most important cost item is namely the “cost” to the patient 
themselves in terms of the emotional trauma suffered and the loss of 
quality of life and independence  
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CLASSIFICATION  
 
Type 1 
 
Type pathology 
 
1A  : Autoimmune beta cell destruction  Insulin deficiency  
1B : Develop insulin deficiency by unknown mechanism causing  
destructive process of beta cells 
Lack immunologic markers 
 
Type II 
 
It is a heterogeneous group of disorders characterized by 
¾ Impaired insulin secretion 
¾ Variable degree of insulin resistance 
¾ Increased glucose production 
 
Distinct genetic & metabolic defects in insulin action & or secretion 
give rise to the common phenotype of hyperglycemia in type – 2 DM 
 
Type – 2 DM is preceded by a period of abnormal glucose 
homeostasis classified as  
 
¾ Impaired fasting glucose (IFG) 
¾ Impaired glucose tolerance (IGT) 
 
Diagnosis 
 
The National Diabetic Date Group & World Health Organization 
have issued a diagnostic criteria for DM-2 based on the following facts: 
 
¾ RBS >200 mgs / dl or > 11.1 m mol / l with symptoms of DM 
(polyuria, polydipsia, weight loss) 
 
¾ FBS > 126 mgs / dl or > 7.0 m mol / L 
 
¾ 2 hr plasma glucose (during oral GTT) > 200 mgs / dl or >11.1 m 
mol / L  (Not recommended a  part of routine screening) 
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TABLE NO 3.4 : DIAGNOSIS OF DIABETES MELLITUS 
Terms  Definition
Random blood glucose (RBS) Blood glucose levels with out regard to 
time since last meal  
Fasting blood glucose (FBS) Blood glucose levels when there is no 
caloric intake for past 8 hrs 
2 Hr plasma glucose  
(During Oral GTT) 
The test should be performed using a 
glucose load containing the equivalent 
of 75 gms anhydrous glucose dissolved 
in water  
 
 
Type 2 DM 
 
 
Etio – pathogenesis 
 
¾ Insulin resistance 
¾ Abnormal insulin secretion  
 
 
Most studies support the view that insulin resistance precedes 
insulin secretary defects and that diabetes develops only if insulin secretion 
becomes inadequate. 
 
Genetic considerations 
 
Type 2 DM has a strong genetic component 
 
¾ The concordance of type 2 DM in identical twins is between 70 and 
90% 
 
¾ Individuals with a parent with type 2 DM have an increased risk of 
diabetes; if both parent have type 2 DM, the risk approaches 40% 
 
¾ Insulin resistance, as demonstrated by reduced glucose utilization in 
skeletal muscle, is present in may non diabetic, first – degree 
relatives of individuals with type 2 DM 
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¾ Major genes that predispose to this disorder have yet to be 
identified, but it is clear that the disease is polygenic and 
multifactor. The gene for the protease, calpain 10, is associated with 
type 2 DM in Hispanic and some other populations 
 
[ 
¾ Various genetic loci contribute to susceptibility, and environmental 
factors (such as nutrition and physical activity) further modulate 
phenotypic expression of the disease. However, definition of the 
genetic susceptibility remains a challenge because the genetic defect 
in insulin secretion or action may not manifest itself unless an 
environmental event or another genetic defect, such as obesity, is 
superimposed.   
 
 
¾ Mutations of molecules involved in insulin (e.g., the insulin receptor 
and enzymes involved in glucose homeostasis) account for a very 
small fraction of type 2 DM. 
  23
 
 
Pathophysiology  
 
Type 2 DM is characterized by three pathophysiologic abnormalities.  
 
¾ Impaired insulin secretion,  
¾ Peripheral insulin resistance,  
¾ Excessive hepatic glucose production  
 
Pathophysiology of type – II diabetes mellitus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Peripheral insulin resistance or excessive hepatic glucose production  
Pancreatic beta cells compensate by increasing insulin output   
Progressive insulin resistance and compensatory hyperinsulinemia progress as the 
disease progress  
The pancreatic islets in certain individuals are unable to sustain the 
hyperinsulinemic state   
Result : IGT , characterized by elevations in post – prandial glucose. Decreased 
peripheral glucose usage results in post prandial hyperglycemia   
A further decline in insulin secretion and an increase in hepatic glucose production 
lead to overt diabetes with fasting hyperglycemia  
Increased hepatic glucose output predominantly accounts for increased FPG levels  
Glucose 
tolerance 
remains normal, 
despite insulin 
resistance
Ultimately, beta cell failure may 
ensue.  
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Neuropathy and Diabetes Mellitus 
• The prevalence of diabetic neuropathy in patients with type 2 
diabetes is 33 percent over all and more than 50% in patient over 
60yeaer of age  
 
• Diabetic neuropathy correlates with the duration of diabetes and 
glycemic control) type 2 DM. 
 
• May manifest as  
         
1. Polyneuropathy 
2. Mono-neuropathy 
3. Automatic Neuropathy 
 
• Both myelinated and unmyelinated nerve fibers are affected. 
 
• Because the c/f of diabetic neuropathy are similar to those of other 
neuropathies, the diagnosis of diabetic neuropathy should be made  
only after other possible etiologies are excluded. 
 
Poly-neuropathy/Mono-neuropathy : 
• The most common form of diabetic neuropathy is distal symmetric 
polyneuropathy. 
 
• It presents as 
1. Distal sensory loss – most frequent presentation 
2. Hyperesthesia 
3. Paresthesia 
4. Dysesthesia 
 
• Symptoms includes a sensation of following, which begins in the feet 
& spreads proximally 
1. Numbness 
2. Tingling 
3. Sharpness 
4. Burning 
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Any combination of these symptoms may develop as neuropathy 
progresses 
 
• Physical examination reveals 
 
1. Sensory loss 
2. Loss of ankle reflexes 
3. Abnormal position sense 
 
• Pain typically involves lower extremities, is usually present at rest, and 
worsen at night. 
 
• Both an acute (lasting <12 months) and a chronic form of painful 
diabetic neuropathy have been described.  
 
• As diabetic neuropathy progresses, the pain subsides & eventually 
disappears, but a sensory deficit in the lower extremities persists. 
 
• Neuropathic pain develops in some of these individuals, occasionally 
preceded by improvement in their glycemic control. 
 
 
Diabetic Neuropathy 
If may be accompanied by – motor weakness 
 
 
 
 
 
 
 
 
 
Definition – “is  a syndrome characterized by severe disabling pain 
in the distribution of one or more nerve root” 
Intercostals or truncal radiculopathy  Involvement of lumbar plexus or femoral nerve   
Pain over thorax or abdomen    Pain in hip & or thigh & may be associated 
with muscle weakness in the hip flexors or 
extensors (diabetic amyotrophy)  
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Treatment of Diabetic Neuropathy  
 
• Improved glycemic control should be pursued and will improve 
nerve conduction velocity, but the symptoms of diabetic neuropathy 
may not necessarily improve.  
 
 
• Avoidance of neurotoxins (alcohol), supplementation with vitamins 
for possible deficiencies (B12, B6, folate). 
 
• Symptomatic treatment  
 
• Since pain of acute diabetic neuropathy may resolve over the first 
year, analgesics may be discontinued as progressive neuronal 
damage from DM occurs. 
 
• Chronic, painful diabetic retinopathy is difficult to treat but may 
respond to  
 
1. Tricyclic antidepressants – amitryptline, desipramine, 
nortriptyline  
 
2. Gabapentin 
 
3. NSAIDs (avoid in renal dysfuntions) 
 
4. Others (mexlitne, phenytoin, carbamazepine, capsaicin cream) 
 
• Referral to pain management center may be necessary. 
 
Lower extremity complications 
o Foot ulcers and infections are a major source of morbidity in 
individuals with DM. 
 
o The reasons for the increased incidence of these disorders in DM 
involve the interaction of several pathogenic factors.  
 
¾ Neuropathy 
¾ Abnormal foot biomechanics 
¾ Peripheral arterial disease 
¾ Poor wound healing. 
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NEUROPATHY 
 
 Neuropathy is present in over 80 percent of patients with foot ulcers 
 
Peripheral Sensory Neuropathy 
 
 Interferes with normal protective mechanisms and allows the patient 
to sustain major or repeated minor trauma to the foot, often without 
knowledge of the injury. 
 
Motor and Sensory Neuropathy 
                         Lead to abnormal foot muscle mechanics and to structural changes in 
the foot (hammer toe, claw toe deformity, prominent metatarsal head, 
charcot joint). 
 
 
Autonomic Neuropathy 
 
 Results in anhidrosis and altered superficial blood flow in the foot, 
which promote drying of the skin and fissure formation. 
 
 
Peripheral arterial disease and poor wound healing  
 
 Impede resolution of minor breaks in the skin, allowing them to 
enlarge and to become infected.  
 
 
Disordered Proprioception 
 
 Causes abnormal weight bearing while walking and subsequent 
formation of callus or ulceration. 
 
 
 Approximately 15% of individuals with DM develop a foot ulcer, and 
a significant subset will ultimately undergo amputation (14 to 24%) risk 
with that ulcer or subsequent ulceration.  
 
           Foot problems are an important cause of morbidity in patients with 
diabetes mellitus 
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Pathogenesis of Diabetic Foot 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
  
 
Physical signs resulting from diabetic neuropathy  
 
 The physical examination may reveal several abnormalities that 
result from neuropathy, such as 
 
¾ Claw toes 
¾ Charcot arthropathy (also called diabetic neuropathic 
anthropopathy) 
 
 
 
Neurological diseases 
Decreased pain sensation   Decreased perception of pressure    
Causes muscle  
imbalance    
Promotes ulcer formation    
Lead to anatomic deformities   
Impairing the microcirculation and the integrity of the skin    
Vascular diseases    
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Pathophysiology of Charcot Arthropathy 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
  
VASCULAR CHANGES IN DIABETES (Levin) 
 
 
1. Atherosclerosis : chronic inflammatory process that can be converted into 
acute clinical events by plaque rupture (Berliner) 
 
 
 Development of atherosclerosis is accelerated in DM leading to 
increased morbidity and mortality. All the large vessels are involve in this 
process and clinical manifestations are apparent as a result of 
atherosclerotic narrowing and thrombosis of coronary, cerebral and leg 
vessels. 
 
 
 
Chronic motor neuropathy often affects the small intrinsic muscles of the feet so that the 
action of the larger muscles in the anterior tibial compartment is unopposed  
This leads to subluxation of the proximal interphalangeal – metatarsal joints   
This leads to claw toe appearance    Increased pressure on the metatarsal heads    
Common site of ulcer development    
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PATHOGENESIS OF DIABETIC ULCERS 
 
Foot pressure abnormalities in diabetic foot 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
 
 
  
 
 
Predisposing Factors for Ulceration  
 
1. Limited joint mobility 
2. Peripheral neuropathy  
3. High plantar pressure 
4. Vascular diseases 
 
Diabetes mellitus  
Neuropathy & limited joint mobility   
Atrophy of intrinsic muscles & clawing   
Pressure transfer from heel & toes to metatarsal heads   
No redistribution of pressure   
Ulceration   
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Biomechanics of Diabetic Foot 
 
Gait cycle: 
 
1. Stance phase 
2. Swing phase 
 
 
 
 
 
 
   
  
 
 
  
 
 
 
 
 
 
Changes in Foot Caused by Diabetes: 
 
1. Peripheral neuropathy 
 
A. Dryness of skin   
B. Callus formation  
 
 
 
 
Stance phase  
Contact phase  Mid – stance phase  Propulsive phase    
To toe off  
opposite limb    
Opposite toe off 
forefoot loading  
and heel lift
Active  
propulsion    
Passive  
lift off    
Plantar  
flexion    
Dorsiflexion  
(max pressure  
on forefoot)    
Heel lift off 
supporting  
side &  ends with  
opposite side heel 
strike    
Opposite heel 
contact  
& terminates with  
supporting side 
toe off     
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2. HIGH PRESSURE AT BONY PROMINENCES  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
3. LIMITED JOINT MOBILITY  
 
 
 
 
 
 
 
  
 
 
 
4.TRAUMA  
 
 
 
 
 
  
 
Decrease plantar tissue thickness     
Weak intrinsic muscles of foot        
Imbalances of flexors & extensors causing clawing 
of foot        
Pulling away fat padding from metatarsal heads         
Unknown etiology        
Collagen abnormality        
Thickening of skin tendons & joint capsules        
Decreased tissue flexibility         
Increase planter pressure         
Trauma      
Intrinsic        Extrinsic       
Repetitive stress from high pressure 
/ callus          
III – Fitting footwear          
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Causation of ulceration 
 
  
 
 
 
 
   
 
 
 
  
 
 
  
 
 
 
CLASSIFICATION OF DIABETIC FOOT 
The Meggitt – Wagner classification is the most well – known and 
validated system for foot – ulcers 
Grade   Description 
 
Gade 0  Pre or post – ulcerative lesion completely epithelialized 
 
Grade 1  Superficial, full thickness ulcer limited to the dermis,  
not extending to the subcutis 
 
Grade 2  Ulcer of the skin extending through the subcutis with  
exposed tendon or bone and without osteomyelitis  
or abscess formation 
 
 Grade 3  Deep ulcers with osteomyelitis or abscess formation. 
 
Grade 4  Localized gangrene of the toes or the forefoot. 
 
Grade 5  Foot with extensive gangrene 
Pressure     
Duration   Increase 
magnitude     
Repetitions 
of pressure  
Relatively low 
pressure for longer 
periods 
High pressure acting 
for short duration  
Foot slap   Mechanical 
of tissues 
fatigue  
Weak dorsiflexion  
Loss of tissue 
integrity  
Cell death     
Wound  
Decrease deceleration 
of forefoot  
Breakdown  
     Rapid strike due to 
increase velocity  
Ischemia  
  34
 
 
 
ULCERS 
 
Diabetic ulcers are classified clinically as 
 
¾ Neuropathic ulcers 
¾ Ischemic ulcers 
¾ Neuro ischemic ulcers 
 
 
 
NEUROPATHIC ULCERS 
 
 
Develop at areas of high plantar pressures. (metatarsal heads, plantar 
aspect of the great toe, heel or over bony prominences in a charcot – type 
foot). Neuropathy is present in about 85-90% of foot ulcers in diabetic 
patients.  Are painless, unless they are complicated by infection. 
 
There is callus formation at the borders of the ulcer. Its base is red, 
with a healthy granular appearance. On examination evidence of peripheral 
neuropathy (hypoesthesia for complete loss of sensation of light touch, 
pain, temperature and vibration, absence of Achilles tendon reflexes, 
abnormal vibration perception threshold, often above 25v, atrophy of the 
small muscles of the feet, dry skin and distended dorsal foot veins) is 
present. However the pattern of sensory loss may vary considerably from 
patient to patient.  
 
The foot has normal temperature of may be warm. Peripheral pulses 
are present and the ankle brachial pressure index in (n) or above 1.3 
 
ISCHEMIC ULCERS 
 
 
Ischemia is a major factor in 38-52% of cases of foot ulcers. These 
ulcers develop on the borders or the dorsal aspect of the feet and toes or 
between toes. They are usually  painful. 
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There is usually redness at the borders of the ulcer. Its base is 
yellowish or necrotic (black). There is history of intermittent claudication.  
On examination signs of peripheral vascular disease (skin is cool, pale or 
cyanosed, shiny and thin, with loss of hair and onychodystrophy; peripheral 
pulses are absent or weak, the ankle – brachial index is <0.9) are present. 
 
 
Non – invasive vascular testing (duplex or triplex ultrasound 
examination, segmental pressures measurement, plethysmograpy) and 
angiography confirm peripheral vasculopathy.  
 
 
NEURO –ISCHEMIC ULCERS (MIXED ETIOLOGY ULCERS) 
   
 Neuro ischemic ulcers have a mixed etiology ie.. neuropathy and 
ischemia 
 
 
PATHOPHYSIOLOGY OF AUTONOMIC NEUROPATHY IN DIABETICS 
 
 
 
 
 
 
 
 
  
 
 
  
 
 
  
 
 Despite these apparent signs of adequate perfusion, the foot is 
vulnerable to local “Micro Vascular” gangrene, will heal very poorly and 
slowly, and will be less able to resist infection. 
The associated autonomic neuropathy can lead to several additional problems  
Sweating  Shunting of blood  
It is diminished or absent  
Lack of autonomic tone in the circulation 
causes shunting of blood from arteries 
directly into veins, by passing the tissues that 
need nutrition.  
As a result of above, the  skin of 
the feet remains dry & has a 
tendency to become scaly & 
cracked   This result in a foot that feels warm 
& has distended veins & bounding 
pulses  
Above factors allows the 
infection to penetrate 
below the skin   
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MANAGEMENT OF DIABETIC FOOT LESIONS 
 
In 1999, the American Diabetes Association recognized several basic 
principles of diabetic wound healing.  
 
¾ Off – loading  
 
¾ Debridement 
 
¾ Use of appropriate dressings 
 
¾ Medical and surgical treatment of infection 
 
¾ Vascular reconstruction and / or amputation or reconstructive foot 
surgery when necessary. 
 
1. OFF LOADING OR PRESSURE RELIEF DEVICES 
 
As has already been mentioned, biomechanical changes are a 
frequent consequence of diabetic neuropathy resulting in an altered 
pressure load on the sole of the foot. Therefore consistent pressure relief is 
an essential precondition for the prevention and healing of foot ulcers.  
 
Total contact casting (TLC) is the most effective method of off – 
loading. A total contact cast in a special cast designed to redistribute the 
patient’s weight off the ulcer site allowing ambulation while the ulcer is 
healing. 
 
OFF LOADING TECHNIQUES.  
Accommodative dressings  - patellar tendon – bearing braces 
Assistive devices    - removable walking braces 
Callus removal    - scotch cast boot 
Foot casts     - shoe cutouts 
Half, wedge or surgical shoes - surgical correction of deformity 
Orthoses     - therapeutic shoes 
Padded hosiery    - total contact casting 
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2.DEBRIDEMENT 
 
Debridement of an ulcer is the corner stone of the management of 
active, acute or chronic wounds. The aim of debridement is to remove 
fibrin (white, yellow or green tissue seen on the bed of an ulcer) and 
necrotic tissue (black tissue) and to produce a clean, well vascularised 
wound bed. 
 
Types of debridement are as follows:- 
 
2.1SHARP SURGICAL (using scalpels) the gold standard for wound 
preparation, removes both necrotic tissue and micro – organisms. Majority 
of diabetics have neuropathy hence, fell no pain, therefore extensive sharp 
debridement or even operations on the feet can be performed without 
anesthesia.  
 
2.2MECHANICAL using wet – to – dry  dressings, hydrotherapy, 
wound irrigation and dextranomers. 
 
2.3ENZYMATIC (using chemical enzymes such as collagenase, 
papain or try or trypsin in a  cream or ointment base) – chronic wounds are 
enzymatically debrided in elderly patients when regular, sharp debridement 
is not possible, e.g.if the necrotic zone is thin, in ulcers with sinuses; and as 
an additional procedure to sharp debridement.  
 
2.4AUTOLYTIC DEBRIDEMENT; using  in vivo enzymes which 
self – digest devitalized tissue such as hydrocolloids, hydrogels, hydrogels, 
and transparent films. This uses the body’s own enzyme and moisture to re 
– hydrate, soften and finally liquefy hard eschar and slough. It is selective, 
as only the necrotic tissue is liquefied and painless to the patient. Its main 
indication is non – infected ulcers with mild to moderate exudates. 
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2.5BIOMECHANICAL WOUND TREATMENT: (BIOSURGERY)  
 
 
Treatment with sterile maggots (larval therapy). 
 
 
The mechanism of action by which the larvae of Lucillia serricate 
(Greeenhottle fly) contribute to the cleaning to the cleaning and healing of 
necrotically coated or infected wounds has yet to be fully elucidated. The 
production of an antibiotic – like agent (also effective against micro – 
organisms resistant to conventional antibiotics). The presence of growth 
factors in the larval secretion, the destruction of bacteria by absorption and 
change in the ph value of the wound are postulate.  
 
Leeches (Hirudo  medicinalis) are also used in amputation surgery. 
Because of their local anti-inflammatory and antithrombotic effect due to 
the formation of hirudin, they are used in areas of critically impaired 
circulation or in the development of hematoma.  
 
After debridement and infection control, the raw are is allowed to 
heal by (i) granulation, (ii) applying split skin graft or local random flaps or 
pedicled muscle flaps.  
 
3. DRESSINGS: broad spectrum of wound dressing materials currently 
are available.  
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TABLE NO 3.5 :ADVANTAGES AND DISADVANTAGES OF 
AVAILABLE TYPES OF DRESSINGS 
Type of dressing  Advantages Disadvantages 
Traditional 
dressings (gauze 
and absorbent 
cellulose) 
Cheap and widely available 
appropriate for gangrenous 
lesions 
Adhere to the wound bed and may 
cause bleeding o removal. Provide 
little protection against bacteria 
contamination  
Films Semi – permeable,. Form 
bacteria barrier. Durable, 
require changing every 4-5 
days. Cheap  
Useful on flat or superficial 
wounds only. Some patients are 
allergic to the adhesive in the 
dressing 
Foams Appropriate for ulcers with 
high production of 
exudates. Provide thermal 
insulation. Easily 
conformable, may be used 
to fill cavities without sinus 
tracts 
Effect difficult to quantify. Not as 
effective and rapid as surgical 
debridement. Not appropriate for 
neuro – ischemic ulcers, which 
produce minimal exudates. 
Wound must be monitored closely 
for signs of infection 
Hydrocolloids Safe and selective, using 
the body’s own defense 
mechanisms. Good for 
necrotic lesions, with light 
to moderate exudates. May 
be used to fill cavities 
without sinus tracts. Can 
be easily used with a shoe. 
Adhesive surface prevents 
slippages. Do not require 
daily dressing changes. 
Cost effective 
Their occlusive and opaque 
nature prevents daily observation 
of the wound. Wound must be 
monitored closely for signs of 
infection. May promote anaerobic 
growth and mask a secondary 
infection.  
Alginates Useful as absorbents of 
exudates. Good for 
infected ulcers. Some 
products have hemostaic 
properties.  
Not appropriate for neuro –
ischemic ulcers, which produce 
minimal exudates. May dry out 
and form plug with in the wound 
bed. Requires painstaking 
removal with the use of large 
amounts of saline.  
Enzymatic 
dressings.  
Good for any wound with a 
large amount of necrotic 
debris, and for eschar 
formation. Promote 
autolysis and fast healing 
decrease maceration of the 
skin and risk of infection 
Costly, must be applied carefully 
only to the necrotic tissue. May 
require a specific secondary 
dressing. Irritation and discomfort 
may occur.  
Medicated 
dressings 
  Data based on animal models and 
cell cultures only.  
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4. SURGICAL MANAGEMENT OF DIABETIC FOOT 
 
¾ Surgical decompression of foot and leg 
¾ Role of amputation 
¾ Role of vascular management  
 
4.1 SURGICAL DECOMPRESSION – 3 types 
FOREFOOT DECOMPRESSION 
 
Web space infection, central plantar space infection are the 
indications. Incision  should be placed deep into plantar space cutting 
plantar  aponeurosis. 
 
PLANTAR SPACE DECOMPRESSION 
 
Main indication is a plantar space infection. Characteristic factor of 
this abscess is disappearance of longitudinal arch and skin crease. The area 
of longitudinal arch may bulge, sole is edematous, incision is made from 
little toe to heel over the medial aspect.  
 
FOOT AND LEG DECOMPRESSION (fasciotomy) 
 
 
Vertical incision for leg and horizontal for foot abscess, cellulitis are 
done.  
 
AVERAGE HEALING TIME 
 
 
Forefoot decompression    - 11 – 38 days 
Plantar decompression    - 12 – 40 days 
Foot and leg decompression   - 12 – 60 days 
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ROLE OF AMPUTATION 
 
 Factors deciding amputation are 
 
1. Age 
2. Nephropathy 
3. Major vessel disease 
4. Gross neuropathy 
5. Presence of gangrene 
6. Involvement of bone 
7. Uncontrolled diabetic ketoacidosis 
8. Septicemia 
 
TYPES OF AMPUTATION  
 
1. Toe amputation  
2. Great toe amputation 
3. Other toes amputation  
4. Ray amputation  
5. Trans metatarsal amputation 
6. Below knee amputation  
 
5. VASCULAR MANAGEMENT 
 
1. Role of pentoxyphylline 
2. Antiplatelet durgs 
3. Surgery – Endarterectomy / Bypass Procedure  
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6. ADJUVANT THERAPY FOR WOUND HEALING  
 
1. Cultured human dermis and cultivated equivalents  
2. Hyperbaric oxygen therapy 
3. Ketanserin 
4. Growth factors 
5. Granulocyte – colony stimulating factor  
6. Electrical stimulation  
7. Sulodexide 
8. Hyaff 
9. Low level laser therapy  
 
RECOMMENDATIONS. 
 
¾ The feet should be examined at least annually in patients with type 2 
diabetes & in those with type – 1 diabetes for more than 5 years.  
 
¾ A detailed neurological examination & assessment for peripheral 
vascular disease should be performed 
 
¾ We recommend using the quantitative foot assessment for 
neurological symptoms & sings described above, including the 5.07 
U mono-filament test 
 
¾ Patients should be considered at particularly high risk for future 
plantar ulceration if they have 
 
¾ A previous H/o foot ulceration or amputation 
 
¾ Neuropathic foot deformities, especially with overlying bunions or 
calluses,  
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PROPHYLACTIC FOOT CARE 
 
It is important that prophylactic advice on foot care be given to any 
patient whose feet are at high risk. The recommendations for prophylactic 
foot care are –  
 
Avoid  
 
1. Smoking  
2. Walking barefoot 
3. The use of heating pads or hot water bottles 
4. Stepping into a bath without checking the temperature 
 
 
The feet should be: 
 
¾ Washed daily in tepid water 
¾ Mild soap should be used and the feet should be dried by gentle 
patting 
¾ A moisturizing cream or lotion should then be applied. 
 
Toe Nails: 
 
 
¾ Trimmed to the shape of the toe 
¾ Filed to remove sharp edges.  
 
Shoes 
 
¾ The patient’s shoes should be snug, not tight, 
 
¾ Patients who have misshapen feet or have had a previous foot ulcer 
may benefit from the use of special customized shoes.  
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¾ A prospective study found that shoe variables other than the 
recommendation for customized shoes (e.g. style, width, length or 
type of shoe) had no preventive effect. 
 
 The use of customized shoes,  however, reduced the development of 
new foot ulcers from 58 to 28 percent over one year of follow – up in a 
second report 
 
Socks: 
 
¾ Cotton  
¾ Loose fitting 
¾ Should be changed every day 
 
Inspection of feet: 
 
 The feet should be inspected daily, looking between and underneath 
the toes and at pressure areas for skin breaks, blisters, swelling, or redness. 
The patient may need to use a mirror or if vision is impaired, have someone 
else perform the examination. 
 
 
Examination of foot by medical person: 
 
 
 A particularly effective strategy is to make specific recommendations 
to the patient in the form of a “contract’. And to advise the patient to 
request that his or her feet be examined at every visit to the doctor or nurse. 
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IDEAL DIABETIC FOOT TEAM 
 
Diabetic foot requires a team work to save the foot. The team 
consists of: 
 
¾ General surgeon 
¾ Dietician 
¾ Podiatrist 
¾ General physician 
¾ Microbiologist 
¾ Pharmacist 
¾ Nurse 
¾ Orthopaedician 
¾ Vascular surgeon 
¾ Plastic surgeon 
¾ Physiotherapist 
¾ Laboratory specialist (foot Pressures) 
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HYPOTHESIS 
 
Is low level laser therapy given daily with clustered probe at 2.5 m 
W at 5KHz frequency, 10,600 nm wavelength (CO2 Laser) for 2 - 5 min 
depending on wound area at a dose of 8 - 10 J/cm2 along with conventional 
treatment compared to conventional therapy alone, effective in reducing the 
mean percentage in area reduction significantly in patients with diabetic 
foot ulcers more than 3 weeks old admitted in C M C H under surgery 
department.  
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MATERIALS AND METHOD 
 
STUDY DESIGN-RANDOMIZED CLINICAL TRIAL: 
 
 The present study  was carried out at Coimbatore medical college 
hospital for a period of two years. 40 patients with diabetic foot ulcers 
participated in present study, using protested and pre- designed Performa 
based on which the study was randomized into either group using a 
computerized randomization chart. Out of 40 partcipants,20took treatment 
in form of conventional therapy and the remaining  20 had treatment with 
low level laser therapy(LLLT) along with conventional therapy. 
 
SAMPLE SIZE: 
 
Total of 40 patients of which 20 patients in control group received 
conventional therapy and study group received low level laser therapy 
along with conventional therapy  (in form of betadine and saline dressings 
and wound debridements). 
 
PERIOD OF STUDY 
 
 A randomized control study from October 2007 to September 2009. 
 
INCLUSION CRITERIA: 
 
¾ Type 2 diabetes mellitus 
¾ Diabetics between 40 and 70yrs of age 
¾ Size of ulcer more than 8X8X1.5cm 
¾ Duration of ulcer more than three weeks duration 
¾ Grade I diabetic wound Wagner’s classification 
¾  Negative wound cultures 
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EXCLUSION CRITERIA: 
 
¾ Pulse less limb 
¾ Immunocompromised patients 
¾ Hemoglobin level 10mg 
¾ Associated osteomyelitics 
¾ Cardiac connective disorder 
¾ Cellulitis 
¾ Diabetic ketoacidosis 
¾ Diabetic gangrene 
¾ Connective tissue disorder 
¾  Uncontrolled hypertension and renal failure 
¾ Surgical interventions done during part 15 days 
¾  Pregnant women 
¾   Infected ulcers 
¾  Patients who discontinued treatment while under study due to  
migration or intolerance to laser therapy also were excluded. 
 
After  participants enrolled to study, informed consent taken from 
patient, after explaining the procedure. Patients randomized with the 
help of a computer generated randomization chart. Participants of study 
group received laser therapy along with conventional treatment, while 
those in control group received only   conventional mode of treatment. 
 
RECORDING OF DATA: 
 
Detailed history and through clinical examination done in all cases. 
Documentation  done using a stratified  Performa which included 
demographic data of patients, details of investigations, treatment 
provided and measurement of wound  areas of patients enrolled in study. 
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INVESTIGATION: 
 
¾ Hematological,biochemical,microbiological and radiological 
investigation carried out as enumerated in Performa using 
standard procedures. 
 
¾ Urine analysis, fasting blood sugar, renal parameters, culture of 
wound and x-ray of  local part done as out patient procedure. 
 
¾ Peripheral pulses examined manually and  also  confirmed with 
hand held Doppler. 
 
¾ Wound area measured by tracing  the margin of ulcer in a 
transparent  film and counting the number of squares on a graph 
underneath. 
 
PROCEDURE: 
 
Initial wound measurement taken in both the groups before staring 
their respective treatment, that is conventional treatment in control 
group and conventional treatment along with LLLT in study group. 
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TREATMENT OF STUDY GROUP 
 
¾ PART PREPARATION: Saline irrigation given to entire wound 
area to clean the wound before laser treatment and allowed to air 
dry. 
 
¾ Carbon di oxide (co2) laser having wave length of 10,600 A units 
used in the study 
 
¾ Laser irradiation given s per protocol given  below. 
 
TABLE NO 5.1 : LASER IRRADIATION PROTOCOL  
 
Power Duration  Energy 
Density 
No.of Days  
2 mW 4 sec /cm2 8J / cm2 Day 01 Scanning 
dose 
2.5 mW 4 sec / cm2 10 J / cm2 Day 
04,07,10,13,16,19 
Over entire 
wound area  
 
¾ On day 01, scanning dose given at a dose of 8J/cm2, tolerability, 
reactions or any side effects to laser therapy in patients noted. 
 
¾ If patients tolerates scanning  dose with no adverse effects, treatment 
schedule is continued once in 3 days, i.e. on day 04,07,10,13,16,19  
with a dose of 10J/cm2. 
 
¾ After treatment, an adhesive sterile bandage applied over the treated 
wound. Subjects instructed to remove bandages only to shower, 
reapply new bandages after the shower and replace bandages if 
removed. 
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¾ Conventional treatment in form of daily moist dressing using saline, 
betadine, wound debridement given as and when required. 
 
¾ All subjects compiled with treatment for entire 20 days period. 
 
 
SAFETY MEASURES: 
 
¾ Both subject and the administrator wore laser safety goggles before, 
during and after treatment to prevent damage to retina in study 
group. 
 
¾ All investigators wore latex gloves during procedures. 
 
CONTROL GROUP: 
 
¾ All patients instructed to both daily in morning and wash wound 
with plain soap & water wound and allow it to air dry. 
 
¾ conventional treatment in form of moist dressing using saline, 
antibiotic treatment, wound debridment given daily depending on 
wound. 
 
¾ After treatment, sterile dressing given and patients instructed to 
remove it only next day for shower. 
 
¾ Al patients compiled with treatment for 20 days. 
 
¾ All investigators wore later gloves during procedure. 
 
 
STERILIZATION: 
 
All instruments and dressing materials sterilized before use, by 
standard methods. 
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ASSESSMENT OF WOUND: 
 
¾ Subjects from both groups returned on 20th day for assessment of 
wound and measuring of wound. 
 
¾ Efficiency of low-level laser therapy (LLLT) assessed by measuring 
wound area on day 01 and day 20th  in both control & study group 
and subjected to statistical analysis. 
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OBSERVATION AND RESULTS  
TABLE NO 6.1 : SEX DISTRIBUTION 
CASES 
Sex No.of.Cases Percentage 
Male  12 60
Female 8 40
Total  20 100
 
 
CONTROLS  
Sex No.of.Cases Percentage 
Male  13 65
Female 7 35
Total  20 100
 
 
BOTH 
Sex No.of.Cases Percentage 
Male  25 62.5
Female 15 37.5
Total  40 100
 
 In our study it was observed diabetic foot occurs more commonly in males 
(62.5%) as compared to females (37.5%) 
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TABLE NO 6.2 : AGE OF DISTRIBUTION  
CASES 
 
 
Age  No.of.Cases Percentage 
41-50 4 20
51-60 11 55
> 60 5 25
Total  20 100
 
 
 
CONTROL 
 
 
Age  No.of.Cases Percentage 
41-50 5 25
51-60 12 60
> 60 3 15
Total  20 100
 
BOTH 
 
Age  No.of.Cases Percentage 
41-50 9 25.5
51-60 23 57.5
> 60 8 20.0
Total  40 100
 In our study, it was observed diabetic foot was commonest 
in the age group between 51-60 yrs of age (57.5%) 
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TABLE NO 6.3 : MEAN AGE OF GROUPS  
 
 
STUDY 
GROUP 
 
Age of Population 
Percentage 
Mean SD
Cases 55.24 4.64
Controls  52.84 6.24
 
 
 Mean age groups in cases and controls were 55.24 and 52.84 
respectively which were statistically not significant 
 
Mean age of both the groups is 54.04 
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TABLE NO 6.4 : SOCIO ECONOMIC LEVEL OF PATIENTS 
STUDIED 
 
Socio – Economic Class NO. of Patients Percentage
Poor Socio Economic Status 
(Monthly Income <Rs.1,000) 
30 75.0 
Lower Middle Class  
(Monthly Income : Rs.1,000 – Rs. 6,000) 
7 17.5 
Upper Middle Class  
(Monthly Income > Rs 6,000) 
3 7.5 
Total  40 100 
 
 Greater prevalence of Diabetic foot ulcer was observed in poor socio 
– economic class since most of them were manual laborers prone to trauma 
and due to poor hygiene 
 
TABLE NO 6.5 : TYPE OF FOOT WEAR AMONG PATIENTS 
INSTUDY  
 
Foot Wear Total No. of 
Cases 
Percentage
Walk Bare Foot 15 37.5 
Wear Slippers or Chapels 20 50 
Appropriate foot wear 5 12.5 
Total  40 100% 
 
IN our study, about 87.5% of patient wear no appropriate foot wear. 
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TABLE NO 6.6 : DURATION OF DIABETES  
CASES   
 
Duration in (yrs) Total no. cases Percentage 
1 – 5 12 60
6 – 10 6 30
11 -  15 2 10
Total  20 100
 
 
CONTROL  
 
Duration in (yrs) Total no. cases Percentage 
1 – 5 11 55
6 – 10 7 35
11 – 15 2 10
Total  20 100
 
 
BOTH  
 
Duration in (yrs) Total no. cases Percentage 
1 – 5 23 57.5 
6 – 10 13 32.5 
11 – 15 4 10.0 
Total  40 100.0 
 
In our study it was observed that 57.5% foot ulcers has occurred in patients 
who has diabetes mellitus for durations of one to five years. 
  58
 
 
 
TABLE NO 6.7 : ANTI DIABETIC AGENTS 
CASES    
 
Anti  - Diabetics No. of Cases Percentage 
OHA 14 70
Insulin 6 30
Total  20 100
 
 
CONTROL 
 
Anti  - Diabetics No. of Cases Percentage 
OHA 13 65
Insulin 7 35
Total  20 100
 
 
BOTH  
 
Anti  - Diabetics No. of Cases Percentage 
OHA 27 67.5 
Insulin 13 32.5 
Total  40 100
 
 
In our study, majority of participants were on OHA (67.5%) compared to 
patients taking insulin (32.5%). 
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TABLE NO 6.8 : FASTING BLOOD SUGAR  
CASES    
 
FBS (mgs) No. of Cases Percentage 
80-110mg 6 30
111-125mg 8 40
126-150 mg 6 30
Total  20 100
 
 
CONTROL 
 
FBS (mgs) No.of Cases Percentage 
80-110mg 7 35
111-125mg 8 40
126-150 mg 5 25
Total  20 100
 
 
BOTH  
 
FBS (Mgs) No.of Cases Percentage 
80-110mg 13 32.5 
111-125mg 16 40
126-150 mg 11 27.5 
Total  40 100
 
 
In our study almost (72.5%) had fasting blood sugar  values less than 
125mg%. Only 27.5% had values more than 126mg%. 
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TABLE NO 6.9 : MODE OF DIABETIC FOOT ULCERS   
 
CASES    
 
Type of onset No .of patients Percentage 
Traumatic  12 60
Spontaneous 8 40
Total  20 100
 
 
CONTROL  
 
Type of onset No.of patients Percentage 
Traumatic  13 65
Spontaneous 7 35
Total  20 100
 
 
 
BOTH  
 
Type of onset No.of patients Percentage 
Traumatic  25 62.5 
Spontaneous 15 37.5 
Total  40 100
 
 
 
In our study, Trauma is most common cause of origin of diabetic foot ulcer 
(62.5%) while only (37.5%) are spontaneous in origin. 
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TABLE NO 6.10 : SITE OF ULCER    
 
CASES    
 
Site No.of patients Percentage 
Plantar 13 65
Dorsum 7 35
Total  20 100
 
 
CONTROL  
 
Site No.of patients Percentage 
Plantar 11 55
Dorsum 9 45
Total  20 100
 
 
BOTH    
 
Site No.of patients Percentage 
Plantar 24 60
Dorsum 16 40
Total  40 100
 
  
 In our study, Diabetic ulcer foot more commonly occurs on 
plantar aspect (60%) of foot as compared to dorsal aspect (40%) 
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TABLE NO 6.11 : WOUND CONTRACTION  
 
Group Mean reduction % S.D Median ‘P” value
Control  15.55 2.58 11.3 P<0.001
Study  41.17 3.15 37.67 P<0.001
 
 In our study, it was observed that mean percentage of area 
reduction was higher in study group ( 41.15) as compared to controls (15.5) 
 
 
 
TABLE NO 6.12 : WOUND CONTRACTION RELATED TO 
SITE  
 
Group Plantar Dorsal 
 No Mean
reduction 
% 
S.D No. Mean % 
Reduction 
S.D
Control  11 14.66% 1.72 9 16.27% 2.20
Study  13 38.45% 2.11 7 41.86% 2.34
 
 
 In our study, it was observed patients with ulcers over 
plantar aspect has lesser percentage of mean wound area reduction as 
compared to participants with wound over dorsal aspect, in both control 
group and study group.  
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STATISTICAL ANALYSIS 
 
¾ Statistical analysis was done by using computer programs and 
standard mathematical formula. 
 
¾ Diabetic foot ulcers in the study group had better mean percentage of 
wound  contraction of 41.15 percentage (S.D; 3.15 : median ; 37.67) 
as compared to the control group which had  had mean percentage of 
wound contraction of 15.55 percentage (S.D; 2.58, Median; 11.3) the 
difference in the mean percentage  of area reduction of the two groups 
when studied using  unpaired student T test was found to be 
significant (p<0.001). 
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DISCUSSION 
 
Every surgeon’s desire is that after dressing the wound, it should 
heal without any complications. Successful wound dressing should keep 
the wound moist and devoid of any adverse reactions such as infection, 
maceration and allergy. Diabetic ulcer are chronic wound, stuck in 
inflammation phase and shows cessation of epidermal growth. It is 
projected that developing countries will experience the greatest risk in the 
prevalence of type-2 diabetes in next twenty years. 
 
Low laser therapy (LLT) has shown great promise as a procedure for 
healing of chronic wounds. 
 
 The present study was conducted at Coimbatore Medical College 
Hospital, Coimbatore to study the effect of Low level Carbon-di-oxide 
(Co2) laser therapy on chronic diabetic wound healing dynamics. 
 
1. In present study it was seen that the incidence of diabetic foot ulcers 
were more in males 62.5 % (25 patients) as compared to females 37.5 
% (15 patients). The second national data source, NHDS 
documented higher hospital rates in males suffering from diabetic 
foot ulcer.  
 
2. Diabetic foot ulcers are most common in 6th decade 57.5 % (23 
patients), while only 24.5 % (9 patients) affected in 5th decade. Older 
patients have more chances of developing diabetic foot ulcer. The 
prevalence of diagnosed diabetes increase with age. The NHDS, 
study undertaken in USA between 2002 and 2004 also revealed that 
elderly diabetics has twice risk of developing a foot ulcer. 
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3. Mean age of both study and control group is 54.04 years. Age group 
involved in our study is similar to that reported from Karl Franzens 
University, Austria where mean age is 56.2 years. 
 
4. In our study, about 75 % (30 patients) of participants belonged to 
poor socio-economic status with a monthly income of less than Rs. 
1,000. Most of them are manual laborers who are more prone to 
trauma, poor hygiene, lack of balanced diet are adding to increased 
incidence of diabetic ulcer. The confounding factor is that in 
Government hospital set-up people from high socio-economic status 
do not prefer to get treated. Hence, the exact comparison of 
prevalence among various socio-economic classes was not feasible in 
this study. 
 
5. As most participants are from poor socio-economic status due to 
illiteracy, poverty 87.5 % (35 patients) of our participants do not wear 
appropriate foot wear. Either they are bare foot walkers or wear 
inappropriate sized foot wear. A study by Edmonds et al 1986 shows 
most of diabetic foot ulcers are invariably shoe related and due to 
gait abnormalities. They can be prevented by appropriate sized foot 
wear and educating to avoid tight foot wear. 
 
6.  In our study, it was observed 57.5 % foot ulcers has occurred in 
patients who has diabetes mellitus for one to five years, followed by 
participants having diabetes 6-10 years, constituting 32.5 %  
 
7. Most of patients 67.5 % (27 patients) were on oral hypo-glycemic 
drugs for control of sugar whereas only 32.5 % (13 patients) were on 
insulin. 
 
8. In our study almost 72.5% (29 patients) had FBS values less than 
125mg% and only 27.5% had [11 patients] values more than 126mgs% 
this suggests that participants in both groups had a good glycemic 
control overall. 
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9. In this study 62.5 % of ulcers (25 patients) were traumatic in origin, 
trauma being the triggering factor secondary to neuropathy. About 
37.5 % (15 patients) were spontaneous in origin secondary to blister 
rupture or unnoticed trivial trauma. 
 
10. Around 60 % (24 patients) of participants had ulcer on plantar 
surface of fore foot and remaining 40 % (16 patients) on dorsum of 
foot. Edmonds et al showed 68 % of foot ulcers were on plantar and 
fore-foot areas. As already mentioned inappropriate foot-wear is a 
major reason. 
 
11. It was also observed in our study that patients who had ulcers on 
plantar aspect of foot in control group had mean wound contraction 
of 14.66% [S.D.=1.74] as compared to dorsal wounds of same group 
which had mean contraction of 16.27% [ S.D=2.25]. Similarly the 
mean plantar wound contraction in the study group was 38.45% 
[S.D=2.13] as compared to mean dorsal wound contraction 41.86% 
[S.D = 2.36] suggesting different wound healing dynamics in two 
regions of foot.  
 
12. In our study, participants receiving Low Level Laser Therapy(LLLT) 
along with conventional therapy had better wound contraction 
41.77% [S.D = 3.15] , as compared to the group receiving only 
conventional treatments in whom the mean wound contraction was 
15.55%. [S.D = 2.58], these were found to be statistically significant 
on unpaired student ‘T’ test (p < 0.001), suggesting LLLT enhances 
wound healing in diabetic wounds.  
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FEASIBILITY OF THIS STUDY 
 
1. In a study [low level laser therapy facilitates superficial wound 
healing in humans, a triple – blind sham – controlled study] 
performed by I Ty Hopkins, Todd A.Mcleod, Jeff G. Seegmiller , G. 
David  Baxter published in journal of athletic training 2004; 39(3) 
223-229 repotted results in 22 healthy subjects and shown 55% 
greater wound contraction of cases as compared to controls  
 
2. In present study we have taken  40 patients from type – 2 diabetes 
mellitus with ulcers. Patients were taken up for study based on 
inclusion and exclusion criteria. Out of 40 patient, 20 patient [12 
male, 8 female ] were cases and 20 patient [ 13 males, 7 females] 
were. control.  Participants included in the study group were 
irradiated with 2mw, 8 J/cm2 for 2-5 min on day 01 [scanning dose] 
and then2.5 mw, 10J/cm2 for 2-5min over entire wound surface  for 
once in 3 days in 20 days periods, accounting for seven LLT 
sessions. The wound area  is radiated at prescribed power[2mw or 
2.5mw] for 4 sec /cm2. On calculating, depending on wound area 
LLLT is given for a duration of 2-5min .  The dose delivered is 8-
10J/cm2  
 
(Joules = Power X Duration of exposure) 
  
3. All  40 patient from both study and control group compiled strictly to 
the 20 days treatment schedule. 
 
4. The initial area measurement for both groups taken on day 01 and 
final area measurement on day 21 taken on transparency sheet and 
number of squares counted on a graph paper underneath. 
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5. We applied the following formula to calculate percentage reduction 
in area of wound after 20 days period in period in both cases and 
control groups 
 
(initial area – final area )  
Rate of contraction of wound =      X 100 
         Initial area   
  
6. We have found 15.55% (S.D. = 2.58) contraction of wounds in control 
groups as compared to 41.77% (S.D. = 3.15) contraction of wounds in 
study group. Therefore, study groups are having 25.62% more wound 
contraction as compared  to control group. On applying, unpaired 
student T test (p<0.001) which is significant.  
 
7. In a study [low level laser therapy facilitates superficial wound 
healing in humans, a triple – blind sham – controlled study] 
performed by I Ty Hopkins, Todd A.Mcleod, Jeff G. See miller , G. 
David  Baxter published in journal of athletic training 2004; 39(3) 
223-229 repotted results in 22 healthy subjects and shown 55% 
greater wound contraction of cases as compared to controls 
 
8. But in our study we have found only 25.62% greater wound 
contraction  for cases as compared to controls. The difference in 
results between our study and  mentioned above may be due to the 
fact  that all patients in above study were non – diabetics, otherwise 
healthy humans with no co – morbid illness. Whereas, patients in our  
study were suffering with diabetes mellitus type – 2 and its 
associated complications. 
 
From our study we can say that Low – Level CO2 Laser therapy 
facilitates wound healing in patient suffering from diabetes mellitus type – 
2 along with surgical dressings. 
  69
 
 
 
SIDE EFFECTS 
 
¾ Many patient complained increase in serous discharge from wound 
during  laser therapy. 
 
¾ Very minority of patients had intractable serous discharge and 
itching due to laser therapy, compelling them to discontinue LLLT. 
 
¾ Some patients had mild burning pain lasting for  24 hrs on the day of 
laser session. 
 
¾ The laser therapist had episodes of headache, nausea, irritability, 
straining of eyes during some prolonged laser sessions. 
 
 
 
 
LIMITATIONS OF OUR STUDY 
 
¾ Not a blinded study 
 
¾ Follow up is short to derive conclusion on long term healing of 
ulcers 
 
¾ Cost involved  not analyzed in this study. 
 
¾ LLLT can be used only for ulcers  of moderate size (<15 cm2) to 
produce optimum results 
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RECOMMENDATIONS: 
 
¾ Large scale clinical trials involving large no of participants should be 
done to prove efficacy of LLLT beyond doubt.  
 
¾ Detailed study of LLLT and its hazardous effects is necessary to 
protect patient  and therapist from laser hazards. 
 
 
SCOPE FOR FURTHER STUDY: 
 
There is further scope of study is with low level laser therapy in 
diabetic wounds with respect to anti – infective properties of low level laser 
therapy as shown by recent studies by Andrei p.sommer et al (Anti – 
infective and low level light. A new chapter in photo medicine and laser 
surgery 2007; 25(3) :150 – 158) 
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SUMMARY 
 The incidence of diabetes and complications are on rise. Diabetic 
foot being one of the most common complication.  15% of all diabetics 
develop diabetic ulcers, the most common site being the foot. Diabetes has 
highest risk factor associated with limb threatening ischemia. Trivial 
trauma secondary to neuropathy and distorted pedal architecture causes 
ulcerations. . 20% of admission in diabetics are for foot problems.  
 
 Various modalities of treatment have been developed to aid faster 
healing of diabetic foot ulcers. Course of healing in diabetic foot patients is 
unpredictable and resistant to treatment. 
 
¾ 40 patients of diabetic foot ulcers were studied. They were divided 
into two groups of 20 each. 
 
¾ One group received Low Level Laser therapy along with 
conventional therapy and the control group received treatment in the 
form of conventional therapy. A comparative study was done 
between both groups regarding percentage of  wound area  
reduction.  
 
¾ All patients in the study underwent X-ray of the affected foot, 
patients with stress fractures and osteomyelitis were excluded.  
 
¾ 23 patients were between 51-60 years of age. Males were more 
affected than females. 62.5% males vs 37.5% females.  
 
¾ Mean age of both the groups is 54.04 
 
¾ 87.5%  of patient wear no appropriate foot wear, whom needed 
education regarding foot wear.  
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¾ 57.5% foot ulcers has occurred in patients who has diabetes mellitus 
for durations of one to five years.  
 
¾ Majority of participants were on OHA (67.5%) compared to patients 
taking insulin (32.5%) 
 
¾ Almost (72.5%) had fsting blood sugar values less than 125mg% only 
27.5% had values more than 126mg% 
 
¾ Trauma is most common cause of origin of diabetic foot ulcer 
(62.5%) while only (37.5%) are spontaneous in origin.  
 
¾ Diabetic ulcer foot more commonly occurs on plantar aspect (60%) 
of foot as compared to dorsal aspect (40%)  
 
¾ It was observed patients with ulcers over plantar aspect has lesser 
percentage of mean wound area reduction as compared to 
participants with wound over dorsal aspect, in both control group 
and study group.  
 
 
¾ In our study it was observed that participants receiving LLLT along 
with conventional treatment had better wound contraction of 41.15% 
as compared to the group receiving only conventional treatment in 
whom the mean wound contraction was 15.55% these were  found to 
be statistically significant on unpaired student T test (p<0.001) 
enhances wound healing in diabetic wounds. 
 
 
 Thus, low level laser therapy in the treatment of diabetic foot 
ulcers was found to be more effective, safe, promoter of wound healing, 
and hence can be recommended for the treatment of diabetic foot ulcer 
as an adjuvant to the conventional mode of treatment.  
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CONCLUSION 
 
¾ The wounds in subjects treated with LLLT contracted more than the 
wounds in the non treated group 41.15% vs 15.55% p = <0.001 
significant) . This indicates  LLLT as an effective modality to 
facilitate wound contraction in patients suffering from diabetes and 
can be used as an adjunct to conventional mode of treatment 
(dressings and debridment) for healing of diabetic wounds.  
 
¾ Surgical laser is safe for patient and operating personnel, relatively 
sample to use, rapid in its action and without untoward impact on 
tissue locally or at a distance.  
 
¾ The mechanisms effectively responsible for cell mitotic activity have 
not been clarified yet.  
 
¾ Therefore, we noted that there is a need for research on the action 
and parameters of low-intensity laser .Clinical trials with higher 
sample size are proposed to evaluate the efficacy of low level therapy 
in treatment of this type of wounds. 
 
¾ Progression of foot ulcer from one grade to another can be 
prevented, thus avoiding involvement of bone and its 
complications and save the limb.  
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RESEARCH PARTICIPANT INFORMATION AND CONSENT FORM 
 
 Mr./ Miss/ Mrs.  
 
 You are invited to participate in our research study,  “EFFICACY 
OF LOW LEVEL LASER THERAPY IN ULCER FOOT HEALING IN 
TYPE – 2 DIABETIC PATENTS “ 
 
 Since you are suffering from diabetes and foot ulcer, which is not 
healing since a long time and will be requiring treatment for the same, you 
are eligible to be a part of the study and hence asked to participate. This 
research is about the beneficial effects of Low Level Laser Therapy on your 
foot ulcer and the result of this research will help in a better treatment of 
similar participants in the future. If you agree to be a part of this research, 
we would ask you some relevant clinical history. You are free to not to 
answer to whichever question you think are not relevant. A clinical 
examination will be done and then you will be given Low Level Laser 
Therapy along with the regular betadine dressings for once in three days. 
On the first day the area of the ulcer will be measured and this will be 
repeated at the end of the therapy that is 21st day. 
 
 There are chances you may have a speedy and better recovery with 
this therapy and it will also help in the treatment of participants with 
similar complaints in the future. Your decision of whether or not to 
participate in this study will not affect the quality of treatment you receive. 
Further you may withdraw from the study at any time. All the new 
information collected about you during the course of this study will be kept 
 
confidential to the extent permitted by the law. Any information, which 
identifies you personally, will not be released without your written consent.  
 
 This study doses not have any damaging aspect and there are no 
chances of injury during the course of the study, but if injured the 
investigator is not responsible. There will be no extra cost incurred by you. 
The participation in this study is entirely voluntary and you may withdraw 
from the study at any time. At any time during or after the study, for any 
information you may contact the researcher.  
 
Dr.R.Senthil Kumar 
Room No: 53, PG & CRRI Men’s Quarters 
Coimabatore Medical College Hospital  
Coimbatore – 641 018. 
Ph : 98404 04305 
 
Signature of the participant or legally authorized representative: 
 
Participant’s Name    : 
Signature      : 
Experimenter / Witness’s Name  : 
Signature      : 
Date       : 
Place       : 
PROFORMA 
 
PATIENT IDENTIFICATION DATA: 
Name         IP/OPD NO. 
Age             DOA 
Sex            DOD  
Address  
 
CHIEF COMPLAINTS: 
 
MEDICAL HISTORY: 
 
¾ Peripheral Neuropathy   (         ) 
¾ Nephropathy    (         ) 
¾ Retinopathy     (         ) 
¾ PVD      (         )   
  
 
                       
DIABETIC STATUS: 
 
¾ Type    : 
¾ Duration  :  
¾ Medication   :  Oral Hypoglycemics  Insulin 
       (        )  (        ) 
 
ULCER DETAIL: 
¾ Mode of onset  Traumatic  (        ) 
    Spontaneous  (        ) 
     
¾ Duration 
¾ Progress 
 
 WOUND OBSERVATION: 
¾ Site 
¾ Size 
¾ Shape 
¾ Edge 
¾ Margin  
¾ Floor 
¾ Base 
¾ Discharge 
¾ Surrounding skin 
¾ Contractor 
 
NERUROLOGICAL EXAMINATION 
 
VASCULAR EXAMINATION   Left      Right 
¾ Popliteal a.     (         )  (         ) 
¾ Ant.Tibial     (         )  (         ) 
¾ Post Tibial     (         )  (         ) 
¾ Dorsalis Pedis    (         )  (         ) 
 
ANY FOOT DEFORMITY PRESENT 
¾ Toe deformity     
¾ Bunion 
¾ Charcots foot 
¾ Foot Drop 
 
IF AMPUTATION HAS BEEN DONE 
Specify    Date : 
    Side : 
    Level  : 
       Cause for amputation : 
 
 
 FOOT WEAR ASSESSMENT:    Does Patient wear appropriate shoes 
INVESTIGATION 
 
¾ CBC 
¾ FBS 1st       Date:    
 2nd (24 hr apart)     Date: 
 
¾ Sr.Creatinine 
 
¾ Urea  
¾ Urine :  
  Routine  
  Microscopy  
 
¾ X-ray Foot 
  AP View 
  Lateral View 
 
¾ Wound C/s 
 
 
WOUND AREA MEASUREMETN ON D 1 IN CM2 
 
LLT SPECIFICATIONS 
 
Duration    : 
Power    :  
Frequency    : 
Dose    : 
Once in Three Days : 
ANALYSIS PLAN 
 
TOTAL CALCULATED DOSE OF LLT IN JOULE     
 
Date         Day     LLT 
 
     1    1 
     4    2 
     7    3 
     10    4 
     13    5 
     16    6 
     19    7 
          
 
 
Ulcer area Measurement  
     Day 1               cm2  
 
          
      Day 20             cm2 
 
 
 
                                           Initial Area – Final Area   
% Area Reduction =      X 100 
         Initial Area  
 
 
 
 
 
 
 
 
 
 
KEY TO MASTER CHART 
 
SL.No Serial Number 
IP No In Patient Number 
S Spontaneous 
T Traumatic 
M Male  
F Female 
I Insulin
O Oral Hypoglycemic 
DM Diabetes Mellitus 
Rx Treatment 
FBS Fasting Blood Sugar
N Normal 
NOGC No Organisms Grown
IA Initial Area 
FA Final Area
CA Calculated Area
P Plantar
D Dorsal
C/S Culture Sensitivity 
 
            GRAPHICAL REPRESENTATION 
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GRAPH NO 6.1 : SEX DISTRIBUTION 
No. of Cases 
Percentage
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GRAPH NO 6.2 :AGE DISTRIBUTION 
No.of Cases
Percentage
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GRAPH NO 6.3 : SOCIO ECONOMIC 
LEVEL OF PATIENTS STUDIED
No.of Cases Percentage
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GRAPH NO 6.4 :TYPE OF FOOT WEAR 
No. of Cases
Percentage
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
GRAPH NO 6.5 : DURATION OF DIABETES
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GRAPH NO 6.6 :ANTI DIABETIC AGENTS 
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GRAPH NO 6.7 :FASTING BLOOD 
SUGAR 
No.of Cases 13 16 11 40
Percentage 32.5 40 27.5 100
80-110mg 111-125mg 126-150 Total 
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GRAPH NO 6.8 : MODE OF DIABETIC 
FOOT ULCERS  
No.Of Cases Percentage
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GRAPH NO 6.9 : SITE OF ULCER 
No.of Cases
Percentage
GRAPH NO 6.10 :WOUND 
CONTRACTION 
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MASTER CHART CONTROL  GROUP 
SI.No 
 
IP No O.P.No Age / Sex Onset Site  Anti DMR TBS X-Ray C/S Initial Area 
MM2 
Final area mm2 Ia –fa = ca  % area reduction  
1. 
 
41120 50/M T D O 100 N NOGC 250 200 50 20% 
2 42465 55/M 
 
S P I 135 N NOGC 540 430 110 21.2% 
3 47202 58/M S D O 136 N NOGC 1450 1200 250 17.3% 
4 48315 53/M T P I 150 N NOGC 550 420 130 18.2% 
5 49363 58/F S P O 118 N NOGC 450 360 90 12% 
6 50493 45/M S  D O 145 N NOGC 2150 1850 300 13% 
7 50586 76/M T P O 86 N NOGC 1400 1150 250 17.4% 
8 50798 52/M T P O 120 N NOGC 1950 1650 300 15% 
9 51898 44/M T P I 108 N NOGC 1050 910 140 14.5% 
10 52765 48/F T D O 124 N NOGC 450 380 70 19.6% 
11 53421 44/M T P I 140 N NOGC 350 300 50 14.2% 
12 54921 52/M S P O 94 N NOGC 300 250 50 18% 
13 55655 54/M T D O 122 N NOGC 450 410 40 8.8% 
14 57863 55/M T D O 90 N NOGC 610 490 120 16.5% 
15 58963 62/F S P O 96 N NOGC 560 490 70 12.2% 
16 59215 48/F T D I 116 N NOGC 905 800 105 11.3% 
17 60812 53/M S D O 104 N NOGC 1150 1050 100 13.2% 
18 61151 56/F T P O 112 N NOGC 290 240 50 18% 
19 62851 57/F T P I 115 N NOGC 460 380 80 15.2% 
20 63573 65/F T D I 120 N NOGC 520 400 120 17% 
 
MASTER CHART STUDY GROUP 
SI.No 
 
IP No 
O.P.No 
Age / Sex Onset Site  Anti DMR TBS X-Ray C/S Initial Area 
mm2 
Final area 
mm2 
IA –FA = 
CA  
% area 
reduction  
1. 
 
40120 73/F T P O 120 N NOGC 2050 1550 500 36.8% 
2 41363 52/F 
 
S D O 116 N NOGC 540 320 220 40.4% 
3 40202 55/M T P I 100 N NOGC 580 360 220 41.7% 
4 41311 58/M S P O 96 N NOGC 555 365 190 34.2% 
5 41361 42/M T P O 130 N NOGC 1550 950 400 38.3% 
6 41493 58/F S  D O 115 N NOGC 110 25 85 77% 
7 41580 70/F T P O 136 N NOGC 775 325 450 42% 
8 42586 60/M S P I  90 N NOGC 150 25 125 80% 
9 42597 60/M T P O 138 N NOGC 525 350 175 38.3% 
10 42683 62/M S D O 105 N NOGC 250 125 125 50% 
11 42700 69/M T P I 70 N NOGC 175 50 125 71% 
12 48335 58/F T P O 125 N NOGC 725 550 175 39.2% 
13 49150 48/M T P O 118 N NOGC 875 525 350 40.0% 
14 51199 52/M S D I 124 N NOGC 540 320 220 36.2% 
15 55379 49/M T D O 128 N NOGC 1250 750 500 40% 
16 55365 45/M T D O 14 N NOGC 500 250 250 50% 
17 59335 65/F S P I 88 N NOGC 250 160 90 42.4% 
18 59395 44/F T P O 112 N NOGC 1300 690 610 46.8% 
19 1685 51/F S P O 118 N NOGC 650 400 250 38.4% 
20 1790 53/M T D I 142 N NOGC 850 525 325 38.2% 
 
